About Nuclear Medicine
Nuclear medicine is a specialty branch of medical imaging that involves the use of modalities such as SPECT and PET scans. These technologies help detect and evaluate various disorders in the areas of oncology, cardiology, and neurology. Modalities for nuclear medicine involve the use of a minimal amount of radioisotopes that are either injected, swallowed, or inhaled by an individual. These radioisotopes reach the specific organ targeted by the pharmaceutical compound and emit radiations that can be detected using a scanner or a detector.
Technavio’s analysts forecast the global nuclear medicine market to grow at a CAGR of 8.34% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global nuclear medicine market for 2016-2020. To calculate the market size, the report considers the use revenue generated from the sales of various types of imaging equipment and radiopharmaceuticals that are used for diagnosis and therapeutic purposes.The market is divided into the following segments based on geography:
Press Release
Technavio Announces the Publication of its Research Report – Global Nuclear Medicine Market 2016-2020
Technavio recognizes the following companies as the key players in the global nuclear medicine market: Cardinal Health, Digirad, GE Healthcare, Lantheus Medical Imaging, and Philips Healthcare.
Other Prominent Vendors in the market are:
ABT Molecular Imaging, Advanced Accelerator Applications, AGFA Healthcare, Algeta, Astellas Pharma, Bayer, Bracco Imaging, Brain Biosciences, Capintec, CMR Naviscan, Cubresa, Eczacibasi-Monrol Nuclear Products, FUJIFILM Holdings, IBA Molecular Imaging, ISOLOGIC Innovative Radiopharmaceuticals, Jubilant DraxImage, Mallinckrodt, Mediso Medical Imaging System, Mirada Medical, Navidea Biopharmaceuticals, Nordion, Piramal Imaging, Positron Pharmaceutical Company, RadioMedix, SHINE Medical Technologies, Sophie Biosciences, Toshiba Medical Systems, Triad Isotopes, and Voxel.
Commenting on the report, an analyst from Technavio’s team said: “Partnerships for development of nuclear medicine is a key trend. Many nuclear medicine and nuclear imaging companies are forming partnerships to solve longstanding radiopharmaceutical concerns in medical imaging and increase the market share of vendors. These partnerships will increase the production of low cost radiopharmaceuticals, which will boost the growth of the market.”
According to the report, the demand for radiopharmaceuticals is high in the global nuclear medicine market. Most radioactive compounds are used for diagnostic procedures and a few are used for therapeutic purposes. Regulatory bodies such as the FDA are approving radiopharmaceuticals for expanded use.
Further, the report states that radiopharmaceuticals are highly expensive and can be a financial burden for the healthcare industry if nuclear medicines stay unutilized. Studies show that around 16% radiopharmaceuticals in the US remained unutilized in 2014.
Companies Mentioned
Cardinal Health, Digirad, GE Healthcare, Lantheus Medical Imaging, Philips Healthcare, ABT Molecular Imaging, Advanced Accelerator Applications, AGFA Healthcare, Algeta, Astellas Pharma, Bayer, Bracco Imaging, Brain Biosciences, Capintec, CMR Naviscan, Cubresa, Eczacibasi-Monrol Nuclear Products, FUJIFILM Holdings, IBA Molecular Imaging, ISOLOGIC Innovative Radiopharmaceuticals, Jubilant DraxImage, Mallinckrodt, Mediso Medical Imaging System, Mirada Medical, Navidea Biopharmaceuticals, Nordion, Piramal Imaging, Positron Pharmaceutical Company, RadioMedix, SHINE Medical Technologies, Sophie Biosciences, Toshiba Medical Systems, Triad Isotopes, Voxel.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook